Revive Therapeutics (RVV.C) provided an update on their FDA Phase III clinical trial to evaluate the safety and efficacy of Bucillamine in patients with mild to moderate Covid-19. …
RVV.C
Revive Therapeutic (RVV.C) announced they have received positive results from a pre-clinical study evaluating the efficacy of psilocybin for the treatment of mild traumatic brain injury (TBI) in a rodent model of…
+135k shares in a downturn, my man The psychedelics sector is down bad this week. Just look at the psychedelics ETF PSYK.NE. It’s not an alarm or…
Revive Therapeutics (RVV.C) provided an update on their Phase 3 clinical trial for bucillamine for COVID-19 today. Primarily, the update’s about funding and more specifically their recent $23 million…
Humming in Q1 I’ve had a rough year, but Revive (RVV.C) sure hasn’t. With a portfolio based around psychedelics, cannabis, and diseases – this company has made 3…
Revive Therapeutics (RVV.C) advanced the December 21 deal with Newscope Capital (PHRM.C) past a binding LOI and into a purchase agreement to acquire psilocybin intellectual property from Newscope’s subsidiary,…
Mother nature Am I a true hippy, or do I have an impulsive personality that morphs and changes due to a lack of identity? My therapist thinks…
Revive Therapeutics (RVV.C) and 17 other companies in the United States and Canada joined the first psychedelic exchange-traded fund, managed by Horizons ETF management today, according to a press…
Revive Therapeutics (RVV.C) entered into a sponsored research agreement and license agreement with North Carolina State University (NC State), developing a biosynthetic version of psilocybin today, according to a…
On December 20, 2020, Revive Therapeutics (RVV.C) inked a non-binding letter of intent for the full rights to PharmaTher’s psilocybin intellectual property, according to a press release. PharmaTher is…